Skip to main content
. 2020 Oct 27;9(1):1832348. doi: 10.1080/2162402X.2020.1832348

Figure 4.

Figure 4.

Comparison T0-T1 of ICs levels in the plasma of mccRCC long responders patients treated with nivolumab